Glucose‐lowering medicines use before and after entry into long‐term care facilities
Authors' conclusion
GLM use peaked in the first 3 months following LTCF entry, driven mainly by insulin, hence, residents may benefit from close monitoring of diabetes treatment during this period.
Study context
- Population
- Long-term care facility (LTCF) residents with diabetes aged ≥65 years, 2015–2019, Registry of Senior Australians National Historical Cohort; median age 84 years
- Participants
- 50,993 residents
- Exposure
- Glucose-lowering medicine (GLM) use 12 months before vs 12 months after LTCF entry
- Outcome
- Prevalence of GLM use and number of DDDs dispensed per 1000 resident-days, estimated quarterly
- Follow-up
- 12 months before and 12 months after LTCF entry
Methodological detailsnational, linked health and aged care data
- National
- Linked health and aged care data
Main finding
As reported in the abstract
Prevalence of GLM use · 9-12 months pre- vs post-entry
Observational data: associations, not effects.
Further findings
Percent
3 months pre-entry
56.8%(95% CI 56.4%–57.2%)
3 months post-entry
61.7%(95% CI 61.3%–62.1%)
- Increased use driven mainly by insulin
Defined daily doses (DDDs) dispensed/1000 resident-days · 9-12 months pre-entry to 9-12 months post-entry
- DDDs/1000 resident-days increased from 1015.2 (95% CI 1002.3-1028.1) to 1253.8 (95% CI 1168.4-1339.3) during the same period
Number of GLMs dispensed and GLM type · 9-12 months post-entry vs 3 months pre-entry
- No marked changes in number of GLMs dispensed or GLM type
Continuation of same GLM among those dispensed a GLM in the 3 months pre-entry · 9-12 months post-entry
- Continued the same GLM (of 22 792 individuals dispensed a GLM pre-entry)
- 50.2%
Original publication
Glucose‐lowering medicines use before and after entry into long‐term care facilities. Diabetes Obes Metab. Published 2 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →